Show Summary Details
Page of

(p. 303) Pharmacotherapy for Obesity: Current and Future Treatments 

(p. 303) Pharmacotherapy for Obesity: Current and Future Treatments
(p. 303) Pharmacotherapy for Obesity: Current and Future Treatments

Orli Rosen

and Louis J. Aronne

Page of

PRINTED FROM OXFORD CLINICAL PSYCHOLOGY ONLINE ( © Oxford University Press, 2020. All Rights Reserved. Under the terms of the licence agreement, an individual user may print out a PDF of a single chapter of a title in Oxford Clinical Psychology Online for personal use (for details see Privacy Policy and Legal Notice).

date: 29 October 2020

Chapter 46 discusses pharmacotherapy for obesity, and details the guidelines for use of sibutramine, phentermine, olistat, as well as diabetes medications that cause weight loss (metformin, glucagon-like peptide-1 analogs), and medications currently in development (Qnexa, Contrave, Empatic, pramlintide, pramlintide/metreleptin, lorcaserin, and tesofensine).

Access to the complete content on Oxford Clinical Psychology requires a subscription or purchase. Public users are able to search the site and view the abstracts and keywords for each book and chapter without a subscription.

Please subscribe or login to access full text content.

If you have purchased a print title that contains an access token, please see the token for information about how to register your code.

For questions on access or troubleshooting, please check our FAQs, and if you can't find the answer there, please contact us.